Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alpharma Generic Exclusivity Deals Will Face FTC Scrutiny Under Settlement

Executive Summary

Alpharma has agreed to limits on future agreements with generic companies involving licensing of 180-day "first-to-file" exclusivity as part of a settlement with the Federal Trade Commission

You may also be interested in...

Purepac gabapentin approval on hold

Purepac/Teva will not be able to market gabapentin capsules before December unless the companies reach an agreement with Apotex to settle a lawsuit challenging generic exclusivity rights to Pfizer's Neurontin. A federal appeals court granted Apotex' request to stay the ANDA approval of "first filer" Purepac pending resolution of Apotex' lawsuit against FDA. Purepac received approval in September 2003 but has not yet launched due to pending litigation; the company has selectively waived its 180-day exclusivity to Teva. The court's decision does not affect approvals Ivax has on tablet forms of gabapentin; Ivax says it is still considering when to launch...

Teva, Ivax Move Closer To Marketing Generic Gabapentin

Teva and Ivax are moving into position to consider "at risk" launches of generic gabapentin (Pfizer's Neurontin)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts